129 related articles for article (PubMed ID: 18722854)
41. HPV vaccines to prevent cervical cancer and genital warts: an update.
Dochez C; Bogers JJ; Verhelst R; Rees H
Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
[TBL] [Abstract][Full Text] [Related]
42. CDC panel backs routine HPV vaccination.
Kuehn BM
JAMA; 2006 Aug; 296(6):640-1. PubMed ID: 16896097
[No Abstract] [Full Text] [Related]
43. The future of cervical cancer prevention: human papillomavirus vaccines.
Cadman L
J Fam Health Care; 2008; 18(4):131-2. PubMed ID: 18754553
[TBL] [Abstract][Full Text] [Related]
44. [Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools].
Dillner J; Andrae B; Westermark B
Lakartidningen; 2006 Nov 1-7; 103(44):3377-9. PubMed ID: 17152260
[No Abstract] [Full Text] [Related]
45. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
[TBL] [Abstract][Full Text] [Related]
46. Harnessing the power of prevention: human papillomavirus vaccines.
Mayeaux EJ
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
[TBL] [Abstract][Full Text] [Related]
47. HPV vaccine for cancer and wart prevention.
Kolber MR; Lindblad AJ
Can Fam Physician; 2015 Jan; 61(1):50. PubMed ID: 25609521
[No Abstract] [Full Text] [Related]
48. Human papillomavirus, vaccines and women's health: questions and cautions.
Lippman A; Melnychuk R; Shimmin C; Boscoe M
CMAJ; 2007 Aug; 177(5):484-7. PubMed ID: 17671239
[No Abstract] [Full Text] [Related]
49. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
50. Vaccinating adolescent girls against human papillomavirus-Who decides?
McRee AL; Reiter PL; Brewer NT
Prev Med; 2010 Apr; 50(4):213-4. PubMed ID: 20153358
[No Abstract] [Full Text] [Related]
51. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid.
Cook RL; Zhang J; Mullins J; Kauf T; Brumback B; Steingraber H; Mallison C
J Adolesc Health; 2010 Dec; 47(6):596-9. PubMed ID: 21094437
[TBL] [Abstract][Full Text] [Related]
52. Testing a model for parental acceptance of human papillomavirus vaccine in 9- to 18-year-old girls: a theory-guided study.
Reynolds D; O'Connell KA
J Pediatr Nurs; 2012 Dec; 27(6):614-25. PubMed ID: 22020360
[TBL] [Abstract][Full Text] [Related]
53. Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS).
National Advisory Committee on Immunization (NACI)
Can Commun Dis Rep; 2007 Feb; 33(ACS-2):1-31. PubMed ID: 17520773
[No Abstract] [Full Text] [Related]
54. Anticipating full benefits from the new papillomavirus vaccines.
Griffiths PD
Rev Med Virol; 2007; 17(1):1-3. PubMed ID: 17173349
[No Abstract] [Full Text] [Related]
55. Debate begins over public funding for HPV vaccine.
Comeau P
CMAJ; 2007 Mar; 176(7):913-4. PubMed ID: 17374749
[No Abstract] [Full Text] [Related]
56. Human papillomavirus vaccine trials and tribulations: Clinical perspectives.
Handler MZ; Handler NS; Majewski S; Schwartz RA
J Am Acad Dermatol; 2015 Nov; 73(5):743-56; quiz 757-8. PubMed ID: 26475534
[TBL] [Abstract][Full Text] [Related]
57. HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior?
Juraskova I; Bari RA; O'Brien MT; McCaffery KJ
Womens Health Issues; 2011; 21(1):71-9. PubMed ID: 21185992
[TBL] [Abstract][Full Text] [Related]
58. Human papillomavirus vaccine coverage.
Yuji K; Matsumura T; Miyano S; Tsuchiya R; Kami M
Lancet; 2010 Jul; 376(9738):329-30; author reply 330. PubMed ID: 20674715
[No Abstract] [Full Text] [Related]
59. Genital condylomata are not the human papilloma virus male infection burden.
Bartoletti R; Zizzo G; Cai T; Mirone V
Eur Urol; 2011 Aug; 60(2):268-9. PubMed ID: 21550167
[No Abstract] [Full Text] [Related]
60. Response to: Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324-38.
Hillemanns P
J Med Econ; 2011; 14(2):262-6. PubMed ID: 21385146
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
